Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 03:14, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0809.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0808.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0808.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0807.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0807.jpeg
- 22:30, 12 February 2024 Alen Antony talk contribs created page Mosunetuzumab-axgb (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=mosunetuzumab-axgb |aOrAn=a |drugClass=humanized monoclonal antibody |indicationType=treatment |indication=relapsing or refractory follicular lymphoma in adults after 2 or more lines of systemic therapy. |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, fatigue, rash, pyrexia, and headache. |blackBoxWarningTitle=Cytokine Release Syndrome (CRS) |blackBoxWarningBody=Cytok...")
- 17:40, 12 February 2024 Kosar Doraghi talk contribs created page Spevigo- spesolimab-sbz (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=spesolimab-sbzo |aOrAn=an |drugClass=interleukin-36 receptor antagonis |indicationType=treatment |indication=generalized pustular psoriasis flares in adults |hasBlackBoxWarning=Yes |adverseReactions=asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection. |blackBoxWarningTitle=Warning: Hyp...")
- 22:23, 11 February 2024 Edzelco talk contribs created page Mavacamten (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART...")
- 06:13, 11 February 2024 Alen Antony talk contribs created page Template:AAP (Created page with "Alen Antony Pathil, M.D.[mailto:alenantony657@gmail.com]")
- 19:04, 10 February 2024 Edzelco talk contribs created page Oteseconazole (Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co...")
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA structure.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA structure.png
- 06:17, 10 February 2024 Kosar Doraghi talk contribs created page Ublituximab-xiiy (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory...")
- 06:14, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0806.jpeg
- 06:14, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0806.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0805.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0805.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0799.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0799.jpeg
- 22:35, 7 February 2024 User account Alen Antony talk contribs was created by Alberto Castro Molina talk contribs
- 17:15, 7 February 2024 Kosar Doraghi talk contribs created page LYTGOBI- futibatinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Futibatinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall respons...")
- 05:03, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0790.jpeg
- 05:03, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0790.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0787.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0787.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0788.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0788.jpeg
- 00:47, 7 February 2024 Edzelco talk contribs created page Lutetium (177Lu) vipivotide tetraxetan (Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout...")
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto structure.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto structure.png
- 22:17, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0786.jpeg
- 22:17, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0786.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0785.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0785.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0782.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0782.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0783.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0783.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0784.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0784.jpeg
- 21:18, 6 February 2024 Kosar Doraghi talk contribs created page Deucravacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,...")
- 00:57, 6 February 2024 Edzelco talk contribs created page Nivolumab and relatlimab-rmbw (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im...")
